戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 were started on day -3 to avoid overlap with conditioning therapy.
2 e fludarabine phosphate and cyclophosphamide conditioning therapy.
3 r fludarabine phosphate and cyclophosphamide conditioning therapy.
4 -based nonmyeloablative and irradiation-free conditioning therapy.
5 chronic myeloid leukemia after myeloablative conditioning therapy.
6  with systemic acute GVHD and full-intensity conditioning therapy.
7 mited to patients who received myeloablative conditioning therapy.
8                All patients received similar conditioning therapy; 50 received grafts from unrelated
9 ists of 4 phases: pretransplantation workup, conditioning therapy and infusion, immediate posttranspl
10 lasma antioxidant status was measured before conditioning therapy and serially at days 1, 3, 7, 10, a
11 LC2s) in the lower GI tract are sensitive to conditioning therapy and show very limited ability to re
12  under nonmyeloablative and irradiation-free conditioning therapy, and the blocking the CD40/CD154 pa
13 of liver disease and thrombocytopenia before conditioning therapy as dominant risk factors for SOS af
14                                        After conditioning therapy, both transduced and untransduced P
15                                              Conditioning therapy consisted of alemtuzumab, fludarabi
16  therapeutic radioligand-before conventional conditioning therapy followed by autologous or allogenei
17  who successfully underwent nonmyeloablative conditioning therapy followed by infusion of partially m
18 used intravenous busulfan and fludarabine as conditioning therapy for allogeneic hematopoietic stem c
19 transplantation after standard myeloablative conditioning therapy for haematological malignant disord
20 having laboratory values before the start of conditioning therapy for unconjugated serum bilirubin co
21 ve days immediately before the initiation of conditioning therapy (fractionated total-body irradiatio
22  malignancies without the need for intensive conditioning therapy immediately before DLI.
23 to a fundamental reevaluation of the role of conditioning therapy in allogeneic transplantation.
24  monoclonal antibodies (mAb) and intensified conditioning therapy, including fractionated total body
25                                              Conditioning therapy, including total-body irradiation a
26           In this study, we show that, after conditioning therapy, intestinal commensal bacteria and
27                                              Conditioning therapy involved 800 cGy total body irradia
28                                              Conditioning therapy involved total body irradiation 2 G
29  high level of safety and fast recovery from conditioning therapy-related side effects after the Bu-F
30 c mechanisms are altered by donor T cells or conditioning therapy, resulting in exacerbation of GVHD.
31 g daily) were administered with the start of conditioning therapy, until at least 120 days after SCT.
32 from haploidentical family members following conditioning therapy using total body irradiation (TBI)
33 doradiotherapy and the start of conventional conditioning therapy were retrospectively analyzed and g
34           Retrospective studies suggest that conditioning therapy with busulfan plus melphalan could
35 -targeting CAR T cells, the patient received conditioning therapy with fludarabine (25 mg/m2 [5 days